Suchergebnisse

AbbVie (ABBV) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.16 per share a year ago. These figures are

For the quarter ended December 2025, AbbVie (ABBV) reported revenue of $16.62 billion, up 10% over the same period last year. EPS came in at $2.71, compared to $2.16 in the year-ago quarter.

The

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the

For those looking to find strong Industrial Products stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ABB (ABBNY) been one of those stocks this

AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4. AbbVie beat estimates for both earnings and sales and also issued an upbeat

AbbVie ABBV is set to report fourth-quarter and full-year 2025 earnings on Feb. 4, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $16.36

Investors looking for stocks in the Manufacturing - Electronics sector might want to consider either Vestas Wind Systems AS (VWDRY) or ABB (ABBNY). But which of these two companies is the best

AbbVie Inc. ABBV reported fourth-quarter 2025 adjusted EPS of $2.71, which beat the Zacks Consensus Estimate of $2.66. The reported figure also exceeded the company’s guidance of $2.61-$2.65 issued

AbbVie ABBV had an encouraging year in 2025, registering a sales growth of about 8.5% year over year at constant exchange rates. This number is impressive for a company that has been facing

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for